Has laser photolysis the potential to postpone the need for cataract surgery?

Article

This question was posed by Irv Arons who said: “In reviewing an article about proposed new uses for the femtosecond laser, I came across a term that I had not heard of before ? laser photolysis.....

This question was posed by Irv Arons who said: “In reviewing an article about proposed new uses for the femtosecond laser, I came across a term that I had not heard of before – laser photolysis. It turns out that laser photolysis with a femtosecond laser is being evaluated to photobleach human lenses and thus postpone the need for cataract surgery.

“Dr Line Kessel and his colleagues in Denmark have tested a technique of scanning the output of a femtosecond laser across human lenses and brought back transparency through photobleaching without damage to the lenses, thereby postponing the need for cataract surgery by from 3 to 7 years. This work was done on donated human lenses from the Cornea Bank NORI in Amsterdam but, if this process becomes feasible for living lenses, the consequences are enormous.

“But, I’m getting ahead of myself. First take a look at Dr.Joseph Colin’s writeup on new applications for femtosecond lasers that appeared in OSN Europe, and then read my treatise on Laser Photolysis. ”

Read more…

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.